title: Emerging Treatments in Schizophrenia: Highlights from Recent Supplementation and Prevention Trials.
abstract: In this column we examine the recent literature regarding adjunctive antipsychotic treatment of schizophrenia. We provide a brief introduction outlining the urgent need for new therapeutics, particularly for the treatment of negative and cognitive symptoms of schizophrenia. We then address (by mechanism of action) the most extensively studied adjunctive antipsychotic treatments. We conclude that adjunctive treatments targeting glutamatergic modulation, as well as supplementation with certain vitamins, have the strongest evidence for use in the treatment of schizophrenia. Further, larger randomized, controlled trials are needed, focusing on certain subgroups of patients and specific antipsychotic medications.
authors.affiliation: From Harvard Medical School and Department of Psychiatry, Massachusetts General Hospital, Boston (Dr. Brown) and Charlestown (Dr. Roffman), MA.
authors.forename: Hannah E
authors.initials: HE
authors.lastname: Brown
authors.forename: Joshua L
authors.initials: JL
authors.lastname: Roffman
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D018683:Excitatory Amino Acid Agents / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome; D014815:Vitamins / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D014150:Antipsychotic Agents; D018683:Excitatory Amino Acid Agents; D014815:Vitamins